
EMA Releases Medication Error Guidelines
The European Medicines Agency releases guidelines for addressing and reporting risks associated with medication errors.
The European Medicines Agency has released two draft guidelines addressing the reporting, assessment, and prevention of medicine errors. The agency defines medicine errors as “unintended mistakes in the prescribing, dispensing and administration of a medicine that could cause harm to a patient.” The EMA guidelines are part of the EMA/Heads of Medicines Agencies joint action plan, developed with the European Commission’s Patient Safety Quality of Care Working Group.
The first
The second
EMA also released a guideline specifically to address the risk of medication errors related to high-strength insulin. The guideline provides a strategy for proactively and harmoniously addressing risks associated with drugs containing insulin across the European Union.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.